Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) has experienced a decline in its stock price by -1.70 compared to its previous closing price of 1.20. However, the company has seen a fall of -1.92% in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that —Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program.
Is It Worth Investing in Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) Right Now?
The 36-month beta value for CMMB is also noteworthy at 0.46. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMMB is 15.09M, and at present, short sellers hold a 0.44% of that float. The average trading volume of CMMB on June 18, 2025 was 135.07K shares.
CMMB’s Market Performance
The stock of Chemomab Therapeutics Ltd ADR (CMMB) has seen a -1.92% decrease in the past week, with a -15.14% drop in the past month, and a -12.62% fall in the past quarter. The volatility ratio for the week is 2.38%, and the volatility levels for the past 30 days are at 2.33% for CMMB. The simple moving average for the past 20 days is -9.56% for CMMB’s stock, with a -24.82% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
Many brokerage firms have already submitted their reports for CMMB stocks, with Maxim Group repeating the rating for CMMB by listing it as a “Buy.” The predicted price for CMMB in the upcoming period, according to Maxim Group is $4 based on the research report published on May 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $6. The rating they have provided for CMMB stocks is “Outperform” according to the report published on May 06th, 2024.
ROTH MKM gave a rating of “Buy” to CMMB, setting the target price at $7 in the report published on December 19th of the previous year.
CMMB Trading at -6.40% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.74% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMMB starting from OrbiMed Israel Partners Limite, who proposed sale 500,000 shares at the price of $2.03 back on Sep 12 ’24. After this action, OrbiMed Israel Partners Limite now owns shares of Chemomab Therapeutics Ltd ADR, valued at $1,015,000 using the latest closing price.
Stock Fundamentals for CMMB
The total capital return value is set at -1.03. Equity return is now at value -112.99, with -86.96 for asset returns.
Currently, EBITDA for the company is 14672.0 with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.33.
Conclusion
In summary, Chemomab Therapeutics Ltd ADR (CMMB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
